Home / Health / Himachal Drug Samples Fail Quality Tests: 50 Sub-Standard, 7 Spurious
Himachal Drug Samples Fail Quality Tests: 50 Sub-Standard, 7 Spurious
23 Jan
Summary
- Fifty drug samples from Himachal failed quality tests conducted by CDSCO.
- Seven drug samples were declared spurious, indicating potential counterfeiting.
- The affected drugs included various treatments for common ailments and conditions.
In a significant development, the Central Drugs Standard Control Organisation (CDSCO) has identified 50 sub-standard drug samples originating from Himachal Pradesh. Even more concerning, seven of these samples were classified as spurious, suggesting a serious threat to public health.
These failed samples, tested in December 2025, were collected from various manufacturing hubs, with a substantial number originating from the Baddi industrial area. The affected medications span a range of critical treatments, including those for bacterial infections, asthma, high blood pressure, and kidney problems.
This revelation comes at a time when Himachal Pradesh contributes significantly to India's pharmaceutical output, representing approximately 35% of the nation's total drug production annually. In November 2025, a prior CDSCO report also highlighted issues, with 49 drug samples from the state failing quality tests.
Investigations are underway to trace the origin of the spurious samples, as the involved pharma companies have denied their production. State officials have indicated that notices will be issued to all manufacturers whose products did not meet quality standards.
